Targeting high-density lipoproteins: Update on a promising therapy

Archives of Cardiovascular Diseases

Volumn 106, Issue 11, 2013, Pages 601-611

  Verdier, Céline ^a,b   Martinez, Laurent O ^b   Ferrières, Jean ^a,c   Elbaz, Meyer ^a,b   Genoux, Annelise ^a,b   Perret, Bertrand ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b University Hospital of Toulouse   (France)

^c Faculté de Médecine Centre Hospitalo universitaire   (France)

Author keywords

ApoA I transcription; CETP inhibitor; HDL therapy; Mimetic peptides; Niacin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADENOSINE TRIPHOSPHATE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; DIACYLGLYCEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCARBOXYLIC ACID RECEPTOR 1; HYDROXYCARBOXYLIC ACID RECEPTOR 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LAROPIPRANT PLUS NICOTINIC ACID; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; NITRIC OXIDE; PROTEIN BAX; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RECEPTOR; SCAVENGER RECEPTOR BI; SERUM AMYLOID A; SIMVASTATIN; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; BILE; BLOOD VESSEL WALL; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; EARLY TERMINATION OF CLINICAL TRIAL; FLUSHING; HUMAN; INFECTION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ABCA1; ABCG1; ACIDE NICOTINIQUE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE BINDING CASSETTE A1; ADENOSINE TRIPHOSPHATE BINDING CASSETTE G1; APO; APOA-I TRANSCRIPTION; APOLIPOPROTEIN; ATP; CARDIOVASCULAR DISEASE; CETP; CETP INHIBITOR; CHOLESTERYL ESTER TRANSFER PROTEIN; CVD; HDL; HDL-C; HDL-THERAPY; HDL-THÉRAPIE; HIGH-DENSITY LIPOPROTEIN; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; INHIBITEURS DE CETP; LCAT; LDL; LDL-C; LECITHIN CHOLESTEROL ACYL TRANSFERASE; LIVER X RECEPTOR; LOW-DENSITY LIPOPROTEIN; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; LXR; MIMETIC PEPTIDES; NIACIN; P2Y(13); PEPTIDES MIMÉTIQUES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PPAR; PURINERGIC RECEPTOR 13; RCT; REVERSE CHOLESTEROL TRANSPORT; RÉGULATION TRANSCRIPTIONNELLE DE L'APO A-I; SCAVENGER RECEPTOR CLASS B TYPE I; SR-BI; VERY-LOW-DENSITY LIPOPROTEIN; VLDL;

ANIMALS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; DRUG DESIGN; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION MEDIATORS; LIPOPROTEINS, HDL; RISK FACTORS; TREATMENT OUTCOME;

EID: 84888434048     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2013.06.052     Document Type: Review

References (50)

1. World Health Organization. Cardiovascular diseases. Fact sheet No 317. Updated March 2013. Available at: http://www.who.int/mediacentre/factsheets/ fs317/en/index.html.
2. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
3. D.J. Hausenloy, and D.M. Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Heart 94 2008 706 714
4. E. Bruckert Epidemiology of low HDL-cholesterol: results of studies and surveys European Heart Journal Supplements 8 Suppl. F 2006 F17 F22 10.1093/eurheartj/sul036
5. L.O. Martinez, S. Jacquet, and J.P. Esteve Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis Nature 421 2003 75 79
6. A.C. Fabre, C. Malaval, and A. Ben Addi P2Y13 receptor is critical for reverse cholesterol transport Hepatology 52 2010 1477 1483
7. C. Besler, T.F. Luscher, and U. Landmesser Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease EMBO Mol Med 4 2012 251 268
8. J.R. Nofer, B. Kehrel, and M. Fobker HDL and arteriosclerosis: beyond reverse cholesterol transport Atherosclerosis 161 2002 1 16
9. C. Radojkovic, A. Genoux, and V. Pons Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation Arterioscler Thromb Vasc Biol 29 2009 1125 1130
10. L. Camont, M.J. Chapman, and A. Kontush Biological activities of HDL subpopulations and their relevance to cardiovascular disease Trends Mol Med 17 2011 594 603
11. G.D. Norata, A. Pirillo, and E. Ammirati Emerging role of high density lipoproteins as a player in the immune system Atherosclerosis 220 2012 11 21
12. H.B. G., V.S. Rao, and V.V. Kakkar Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response Cholesterol 2011 2011 274629
13. E.R. Mohler 3rd., C.M. Ballantyne, and M.H. Davidson The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study J Am Coll Cardiol 51 2008 1632 1641
14. B.J. Ansell, G.C. Fonarow, and A.M. Fogelman The paradox of dysfunctional high-density lipoprotein Curr Opin Lipidol 18 2007 427 434
15. T. Kelesidis, J.S. Currier, and D. Huynh A biochemical fluorometric method for assessing the oxidative properties of HDL J Lipid Res 52 2011 2341 2351
16. B.J. Ansell, M. Navab, and S. Hama Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756
17. V.S. Kamanna, S.H. Ganji, and M.L. Kashyap Recent advances in niacin and lipid metabolism Curr Opin Lipidol 24 2013 239 245
18. M. Lukasova, J. Hanson, and S. Tunaru Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials Trends Pharmacol Sci 32 2011 700 707
19. S.J. Nicholls Is niacin ineffective? Or did AIM-HIGH miss its target? Cleve Clin J Med 79 2012 38 43
20. Merck. Merck Announces HPS2-THRIVE Study of TREDAPTIVE™ (Extended-Release Niacin/Laropiprant) Did Not Achieve Primary Endpoint. 2012. Available at: http://www.mercknewsroom.com/press-release/prescription-medicine- news/merck-announces-hps2-thrive-study-tredaptive-extended-relea.
21. P.M. Lavigne, and R.H. Karas The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression J Am Coll Cardiol 61 2013 440 446
22. J.W. van der Hoorn, W. de Haan, and J.F. Berbee Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice Arterioscler Thromb Vasc Biol 28 2008 2016 2022
23. L.A. Carlson Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review J Intern Med 258 2005 94 114
24. H. Shinkai Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases Vasc Health Risk Manag 8 2012 323 331
25. S.J. Nicholls, H.B. Brewer, and J.J. Kastelein Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
26. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
27. C.E. Watson, N. Weissbach, and L. Kjems Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function J Lipid Res 52 2011 361 373
28. S.H. Han, M.J. Quon, and K.K. Koh Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators Hypertension 46 2005 1086 1092
29. D. Masson, M. Koseki, and M. Ishibashi Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor Arterioscler Thromb Vasc Biol 29 2009 2054 2060
30. B.F. Voight, G.M. Peloso, and M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
31. N. Serhan, C. Cabou, and C. Verdier Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion Biochim Biophys Acta 1831 2013 719 725
32. R. Barbaras, R. Baron, and M. Goffinet Antiatherosclerotic activity of a new P2Y13 receptor agonist (ct1007900) in animal models Atheroscler Thromb Vasc Biol 32 2012 A493
33. B.J. Arsenault, S.M. Boekholdt, and J.C. Tardif De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough? Eur Heart J 33 2012 1548 1550
34. M. Eriksson, L.A. Carlson, and T.A. Miettinen Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans Circulation 100 1999 594 598
35. M.N. Nanjee, C.J. Cooke, and R. Garvin Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans J Lipid Res 42 2001 1586 1593
36. J.C. Tardif, J. Gregoire, and P.L. L'Allier Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682
37. G. Franceschini, C.R. Sirtori, and A. Capurso 2nd. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family J Clin Invest 66 1980 892 900
38. J.K. Bielicki, and M.N. Oda Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I Biochemistry 41 2002 2089 2096
39. G. Franceschini, L. Calabresi, and G. Chiesa Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice Arterioscler Thromb Vasc Biol 19 1999 1257 1262
40. B.J. Van Lenten, A.C. Wagner, and C.L. Jung Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I J Lipid Res 49 2008 2302 2311
41. L.T. Bloedon, R. Dunbar, and D. Duffy Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J Lipid Res 49 2008 1344 1352
42. F.M. Sacks, L.L. Rudel, and A. Conner Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J Lipid Res 50 2009 894 907
43. R. Waksman, R. Torguson, and K.M. Kent A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
44. J. Chapman Fibrates: therapeutic review J Diabetes Vasc Dis 6 2006 11 20
45. S.N. Friedland, A. Leong, and K.B. Filion The cardiovascular effects of peroxisome proliferator-activated receptor agonists Am J Med 125 2012 126 133
46. P. Natarajan, K.K. Ray, and C.P. Cannon High-density lipoprotein and coronary heart disease: current and future therapies J Am Coll Cardiol 55 2010 1283 1299
47. R.R. Henry, A.M. Lincoff, and S. Mudaliar Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study Lancet 374 2009 126 135
48. S.J. Nicholls, A. Gordon, and J. Johansson Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial J Am Coll Cardiol 57 2011 1111 1119
49. B. Verges, E. Florentin, and S. Baillot-Rudoni Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes J Lipid Res 50 2009 1209 1215
50. C. Besler, K. Heinrich, and L. Rohrer Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J Clin Invest 121 2011 2693 2708